Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Improvements of Distribution Practices Essential for Pricing System Reform: Mr Nagano
June 30, 2008
- Multiparty Group of Diet Members to Discuss Increases in Tobacco Tax
June 30, 2008
- REGULATORY NEWS IN BRIEF
June 30, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 30, 2008
- RNAi Drugs Development Race Heats Up with Entry of Kyowa Hakko
June 30, 2008
- Kyowa Hakko Licenses RNAi Drug for RSV Infection from Alnylam
June 30, 2008
- Annual Meeting of Japanese Society of Chemotherapy
June 30, 2008
- Okayama Univ. to Lead Gene Therapy Research for Prostate Cancer in Asians
June 30, 2008
- R&D NEWS IN BRIEF
June 30, 2008
- Abbott Vascular Applies for XIENCE V
June 30, 2008
- Abbott Japan to Increase Pharma Group Sales to US$1 Bil. within 2 Years
June 30, 2008
- Terumo Acquires Clinical Supply from Eisai
June 30, 2008
- SELF-MEDICATION NEWS IN BRIEF
June 30, 2008
- Taiyo Leads Industry by Production Capacity and Prices: Mr Aratani
June 30, 2008
- NEW PRODUCTS
June 30, 2008
- 29.4% of Prescriptions Substituted Resulting in Savings of \420 Mil. in May: Nihon Chouzai
June 30, 2008
- Record-High 81 Applications Approved in FY2007
June 23, 2008
- REGULATORY NEWS IN BRIEF
June 23, 2008
- Nippon Shinyaku to Include RNA Drug Candidates in Its R&D Pipeline within 2 Years
June 23, 2008
- AnGes MG to Develop Gene Therapy for Mucopolysaccharidosis VI
June 23, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…